---
title: Regulatory challenges and FDAs role in test approvals
videoId: 80OvNaEgmmw
---

From: [[lexfridman]] <br/> 

The conversation with Michael Mina on the Lex Fridman Podcast highlighted significant issues and challenges associated with the approval and deployment of rapid at-home testing for COVID-19, focusing on the role of the U.S. Food and Drug Administration (FDA) in this process. 

## Overview

Michael Mina, a professor at Harvard conducting research on infectious disease and immunology, argues that rapid at-home testing is a powerful solution to managing COVID-19, enabling individuals to detect infectiousness quickly and preserve personal freedom and privacy <a class="yt-timestamp" data-t="00:00:16">[00:00:16]</a>. Despite its potential, such testing has faced significant regulatory hurdles from the FDA.

## FDA's Current Framework

The FDA currently classifies rapid at-home tests as medical devices, which poses a substantial barrier to their wide-scale use <a class="yt-timestamp" data-t="11:06">[11:06]</a>. This classification necessitates that these tests meet strict standards set for medical diagnostics, including sensitivity comparisons with PCR tests, which are considered the gold standard <a class="yt-timestamp" data-t="12:01">[12:01]</a>.

### Medical Device Designation

When declared a medical device, a test must achieve the sensitivity properties expected of a similar medical device. However, this expectation overlooks the different purpose of rapid testing, which is more about indicating infectiousness rather than diagnosing COVID-19 <a class="yt-timestamp" data-t="12:01">[12:01]</a>. Rapid tests are deemed effective public health tools for identifying whether someone is likely to be spreading the virus <a class="yt-timestamp" data-t="05:53">[05:53]</a>.

## Misalignment with Public Health Goals

The regulatory challenges arise partly due to a misalignment between the FDA’s evaluation criteria and the public health goals of rapid testing. The FDA's path for approval doesn't accommodate the criteria relevant to testing for contagiousness, which is the primary utility of at-home tests during a pandemic <a class="yt-timestamp" data-t="13:17">[13:17]</a>.

### Public Health Tool Classification

Mina suggests that these tests should be classified as public health tools rather than medical devices. The FDA itself states that it does not authorize or review public health tools, indicating an opportunity for reclassification. If tests were labeled as public health tools, the responsibility could shift from the FDA to other institutions like the CDC, thus bypassing the stringent requirements designed for medical diagnostics <a class="yt-timestamp" data-t="22:06">[22:06]</a>.

## Potential Solutions

A significant solution proposed by Mina is executive action from the President to reclassify these tests. An executive order could shift the responsibility of evaluating these tools from the FDA to the CDC or similar bodies, thus expediting their approval and distribution <a class="yt-timestamp" data-t="22:06">[22:06]</a>.

## Conclusion 

The conversation emphasized the need for rethinking and restructuring regulatory frameworks to better align with public health needs in a pandemic. The current classifications and expectations for rapid tests hinder their potential to control viral transmission effectively <a class="yt-timestamp" data-t="13:54">[13:54]</a>. This call for a reassessment of the FDA’s role in approving tests highlights a broader need for flexibility and innovation in regulatory approaches to health crises.

> [!info] Related Topics
> 
> - [[transparency_and_regulation_in_drug_approval_processes | Transparency and Regulation in Drug Approval Processes]]
> - [[critique_of_current_governmental_and_regulatory_institutions_like_the_fda | Critique of Current Governmental and Regulatory Institutions like the FDA]]
> - [[challenges_and_breakthroughs_in_drug_discovery | Challenges and Breakthroughs in Drug Discovery]]